ClinicalTrials.gg
Enrolling by invitationNCT07866391Updated Oct 8, 2026

Vitamin D Status and Its Influencing Factors in Zhejiang Province: A Multicenter Cross-Sectional Study

An observational study in Vitamin D Deficiency, sponsored by First Affiliated Hospital of Zhejiang University. Enrolling by invitation at 2 sites in China. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by First Affiliated Hospital of Zhejiang University · Observational

How we know

Updated Oct 8, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Vitamin D Deficiency with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Vitamin D Deficiency · China.

Planned enrollment
2nd of 10
10,000 · median 193
Started
2026
the only one that year
Observational
10 of 28
2 open now
Registered
28th of 28
by date
Lead sponsor
1 of 28
First Affiliated Hospital of Zhejiang University

Among the 28 studies in Vitamin D Deficiency with a site in China, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2026, is one of 10 observational ones, and was the 28th registered.

Vitamin D Deficiency

800 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

Browse Vitamin D Deficiency studies →

Open to participants now

3 of the 28 studies in Vitamin D Deficiency with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Vitamin D Deficiency studies recruiting now, 16 (43%) set no upper age limit and 18 (49%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Vitamin D Deficiency with a site in China, or all of them as a file.
02

Study summary

Vitamin D deficiency is a global public health problem, with an estimated 1 billion people affected worldwide, and large-scale systematic data for Zhejiang Province remain scarce. This is a multicenter, retrospective cross-sectional study. The objectives are to: (1) assess the distribution of serum 25-hydroxyvitamin D [25(OH)D] levels across regions, seasons, and demographic groups in Zhejiang Province and estimate the prevalence of vitamin D deficiency (\<20 ng/mL) and insufficiency (20-29 ng/mL); (2) identify and quantify key determinants of vitamin D status, including environmental exposures (ultraviolet radiation, green coverage), lifestyle (outdoor activity, sun protection), dietary vitamin D intake, and individual characteristics; and (3) provide scientific evidence for targeted intervention strategies, public health policy, and clinical guidelines in Zhejiang Province.

03

Conditions studied

  • Vitamin D Deficiency

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population comprises individuals who underwent serum 25-hydroxyvitamin D [25(OH)D] measurement at multiple hospitals in Zhejiang Province in 2025. The population includes healthy individuals undergoing routine health checkups as well as patients with various chronic diseases (including chronic kidney disease, diabetes, and autoimmune diseases), spanning all age groups.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who completed serum 25(OH)D testing at participating hospitals in this study.
  2. Able to understand the study and voluntarily sign the electronic form via the mobile mini-program.
  3. Able to complete the electronic questionnaire independently or with assistance from family members.

Exclusion criteria

Exclusion Criteria:

  1. Long-term use of medications known to affect vitamin D metabolism (e.g., certain antiepileptic drugs, ).
  2. Refusal to sign or complete the questionnaire; history of immunodeficiency or organ transplantation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Zhejiang

    Patients who completed serum 25(OH)D measurement at participating hospitals in Zhejiang Province in 2025.

06

What researchers measure

Primary outcomes

  1. Serum 25-hydroxyvitamin D [25(OH)D] concentration

    Serum 25-hydroxyvitamin D \[25(OH)D\] concentration, expressed in ng/mL. Measured from existing clinical laboratory results at each participating hospital.

    Time frame: Time frame: Baseline (testing in 2025).

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2026
First posted
Oct 8, 2026
StartEst.
Oct 31, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866391
Collaborators
Bioinformatics Society of Zhejiang Province
Responsible party
Sponsor
First posted
Oct 8, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion